Skip to main content
. 2017 Oct 13;10:4989–4995. doi: 10.2147/OTT.S142686

Figure 2.

Figure 2

(A) PFS in 14 patients after apatinib plus icotinib treatment as the second-line therapy and in 13 patients after apatinib plus icotinib treatment as the third- or later-line therapy. (B) PFS in 11 patients who experienced icotinib monotherapy failure within 6 months and in 16 patients who experienced icotinib monotherapy failure after more than 6 months.

Abbreviations: mPFS, median progression-free survival; PFS, progression-free survival.